Baseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumab

Awada, G. (Speaker)
Özdemir, I. (Contributor)
Schwarze, J. K. (Contributor)
Daeninck, E. (Contributor)
Gondry, O. (Contributor)
Yanina Jansen (Contributor)
Teofila Seremet (Contributor)
Keyaerts, M. (Contributor)
Everaert, H. (Contributor)
Neyns, B. (Contributor)

Activiteit: Talk or presentation at a conference

Description

Poster Presentation - 21P

Periode	14 dec. 2018
Evenementstitel	ESMO Immuno-Oncology Congress 2018
Evenementstype	Conference
Locatie	Geneva, SwitzerlandToon op kaart
Mate van erkenning	International

Gerelateerde inhoud

Prijzen
Best Poster Award
Prijs: Prize (including medals and awards)

Activiteiten
ESMO Immuno-Oncology Congress 2018
Activiteit: Participation in conference

Onderzoeksoutput
Baseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumab
Onderzoeksoutput: Meeting abstract (Journal)